COVID vaccine
A master phase protocol investigates the safety, tolerability and immunogenicity of a variant-adapted BNT 162b2 RNA-BASED vaccine in healthy children ages 6 months to 2 years old.
A master phase protocol investigates the safety, tolerability and immunogenicity of a variant-adapted BNT 162b2 RNA-BASED vaccine in healthy children ages 6 months to 2 years old.